» Articles » PMID: 30441807

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2018 Nov 17
PMID 30441807
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is induced. The goal of this study is to evaluate if SS1P therapy renders mesothelioma tumors more sensitive to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade. We evaluated the ability of SS1P to induce adenosine triphosphate (ATP) secretion and calreticulin expression on the surface of AE17M mouse mesothelioma cells. Both properties are associated with immunogenic cell death. Furthermore, we treated these tumors with intra-tumoral SS1P and systemic CTLA-4. We found that SS1P increased the release of ATP from AE17M cells in a dose and time-dependent manner. In addition, SS1P induced calreticulin expression on the surface of AE17M cells. These results suggest that SS1P promotes immunogenic cell death and could sensitize tumors to anti-CTLA-4 based therapy. In mouse studies, we found that the combination of anti-CTLA-4 with intra-tumoral SS1P induced complete regressions in most mice and provided a statistically significant survival benefit compared to monotherapy. The surviving mice were protected from tumor re-challenge, indicating the development of anti-tumor immunity. These findings support the use of intra-tumoral SS1P in combination with anti-CTLA-4.

Citing Articles

Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology.

Oghalaie A, Hosseini M, Hosseininejad-Chafi M, Eftekhari Z, Behdani M, Kazemi-Lomedasht F Med Oncol. 2024; 41(10):239.

PMID: 39230639 DOI: 10.1007/s12032-024-02478-3.


Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy.

Gholami A, Mohkam M, Soleimanian S, Sadraeian M, Lauto A Microsyst Nanoeng. 2024; 10:113.

PMID: 39166136 PMC: 11333603. DOI: 10.1038/s41378-024-00743-z.


Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer.

Ding Y, Zhou R, Shi G, Jiang Y, Li Z, Xu X Biomater Res. 2024; 28:0041.

PMID: 38911825 PMC: 11192146. DOI: 10.34133/bmr.0041.


The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.

Offin M, Fitzgerald B, Zauderer M, Doroshow D J Cancer Metastasis Treat. 2024; 9.

PMID: 38895597 PMC: 11185317. DOI: 10.20517/2394-4722.2022.140.


Light-enhanced VEGF/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment.

Longva A, Berg K, Weyergang A Front Immunol. 2024; 14:1278000.

PMID: 38173721 PMC: 10762878. DOI: 10.3389/fimmu.2023.1278000.


References
1.
Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G . Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010; 16(12):3100-4. DOI: 10.1158/1078-0432.CCR-09-2891. View

2.
Wolf P, Elsasser-Beile U . Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol. 2008; 299(3):161-76. DOI: 10.1016/j.ijmm.2008.08.003. View

3.
Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

4.
Risberg K, Fodstad O, Andersson Y . Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One. 2011; 6(9):e24012. PMC: 3168478. DOI: 10.1371/journal.pone.0024012. View

5.
Iwai Y, Hamanishi J, Chamoto K, Honjo T . Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017; 24(1):26. PMC: 5381059. DOI: 10.1186/s12929-017-0329-9. View